Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
13 p, 861.9 KB Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation : The phase III TOURMALINE-MM4 trial / Dimopoulos, M.A. (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens. School of Medicine) ; Špička, I. (First Department of Medicine. Department of Hematology. First Faculty of Medicine. Charles University. General Hospital in Prague) ; Quach, H. (Department of Hematology. University of Melbourne. St Vincent's Hospital) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hájek, R. (Department of Hemato-oncology. University Hospital Ostrava. University of Ostrava. Faculty of Medicine) ; Garg, M. (Hematology. Leicester Royal Infirmary. University Hospitals of Leicester NHS Trust) ; Beksac, M. (Department of Hematology. Ankara University) ; Bringhen, S. (Division of Hematology. University of Torino. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino) ; Katodritou, E. (Department of Hematology. Theagenion Cancer Hospital) ; Chng, W.J. (Department of Hematology-Oncology. National University Cancer Institute. National University Health System. Yong Loo Lin School of Medicine. Cancer Science Institute of Singapore. National University of Singapore) ; Leleu, X. (Pôle Régional de Cancérologie. Department of Haematology. Centre Hospitalier Universitaire La Milétrie-Poitiers) ; Iida, S. (Department of Hematology and Oncology. Nagoya City University. Graduate School of Medical Sciences) ; Mateos, M.V. (Hematology. Hospital Universitario de Salamanca. University Hospital of Salamanca. Centro de Investigación del Cáncer. Instituto de Biología Molecular y Celular del Cáncer. Universitario de Salamanca Consejo Superior de Investigaciones Científicas) ; Morgan, G. (Perlmutter Cancer Center. NYU Langone Health) ; Vorog, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Labotka, R. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Wang, B. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Palumbo, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Lonial, S. (Department of Hematology and Medical Oncology. Winship Cancer Institute of Emory University) ; Universitat Autònoma de Barcelona
PURPOSE Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. [...]
2020 - 10.1200/JCO.20.02060
Journal of Clinical Oncology, Vol. 38 Núm. 34 (january 2020) , p. 4030-4041  
2.
12 p, 1.8 MB Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies / Leleu, X. (Service d'Hématologie et Thérapie cellulaire. CHU and Inserm) ; Beksac, M. (Department of Hematology. Ankara University) ; Chou, T. (Niigata Cancer Center Hospital) ; Dimopoulos, M. (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens School of Medicine) ; Yoon, S.S. (Department of Internal Medicine. Seoul National University) ; Prince, H.M. (Epworth Healthcare and Sir Peter MacCallum Department of Oncology. University of Melbourne) ; Pour, L. (Department of Internal Medicine. Hematology and Oncology. University Hospital Brno) ; Shelekhova, T. (Clinic of Professional Pathology) ; Chari, A. (Tisch Cancer Institute. Icahn School of Medicine at Mount Sinai) ; Khurana, M. (Clinical Development. Oncology. Amgen Inc) ; Zhang, J. (Global Biostatistical Science. Amgen Inc) ; Obreja, M. (Global Biostatistical Science. Amgen Inc) ; Qi, M. (Hematology and Oncology. Janssen Research and Development. LLC) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Siegel, D. (John Theurer Cancer Center. Hackensack University Medical Center) ; Universitat Autònoma de Barcelona
The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). [...]
2020 - 10.1080/10428194.2020.1832672
Leukemia and Lymphoma, 2020  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.